IRS1 and Alzheimer disease: In this respect, brain insulin resistance and IRS-1 dysfunction has been detected in AD patients (Talbot et al., 2012), and diabetes drugs represent promising therapies for AD (Ferreira et al., 2018; Boccardi et al., 2019).